NRC
National Research CorporationNASDAQHealthcare$17.16+0.99%ClosedMarket Cap: $390.3M
As of 2026-04-06
Valuation
P/E (TTM)
33.65
PEG
—
P/B
26.99
P/S
2.87
EV/EBITDA
15.52
DCF Value
$13.57
FCF Yield
4.0%
Div Yield
3.2%
Margins & Returns
Gross Margin
56.3%
Operating Margin
16.4%
Net Margin
8.4%
ROE
58.5%
ROA
8.6%
ROIC
14.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $35.2M | 54.3% | $4.7M | $1.8M | $0.08 | $0.16 |
| FY 2025 | $137.4M | 56.3% | $22.6M | $11.6M | $0.52 | $0.64 |
| Q3 2025 | $34.6M | 57.8% | $7.7M | $4.1M | $0.18 | $0.24 |
| Q2 2025 | $34.0M | 56.8% | $1.6M | $-106.0K | $-0.00 | $0.24 |
| Q1 2025 | $33.6M | 56.5% | $8.6M | $5.8M | $0.25 | $0.24 |
| Q4 2024 | $36.9M | 61.1% | $9.6M | $6.6M | $0.28 | $0.24 |
| FY 2024 | $143.1M | 60.2% | $35.2M | $24.8M | $1.04 | $0.60 |
| Q3 2024 | $35.8M | 57.3% | $8.0M | $5.7M | $0.24 | $0.24 |
| Q2 2024 | $35.0M | 61.7% | $8.9M | $6.2M | $0.26 | $0.24 |
| Q1 2024 | $35.3M | 60.8% | $8.8M | $6.4M | $0.27 | $0.24 |
| Q4 2023 | $38.0M | 63.7% | $11.7M | $8.9M | $0.36 | $0.24 |
| FY 2023 | $148.6M | 62.3% | $40.0M | $31.0M | $1.25 | $1.60 |